Trial reportScientific reports2021
Validity of different copeptin assays in the differential diagnosis of the polyuria-polydipsia syndrome.
Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Corticosteroid Treatment for Community-Acquired Pneumonia A Randomized, Double-blind Study- The STEP Trial
Use of Copeptin in the Differential Diagnosis of Diabetes insipidus-a Prospective International Study
Kinetics of Copeptin in Healthy Volunteers - a Prospective International Study
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- The diagnostic and prognostic value of copeptin in patients with acute ischemic stroke and transient ischemic attack: A systematic review and meta-analysis.Cardiology journal · 2022Pooled it
- Copeptin in acute ischemic stroke: a surrogate marker of AVP-system activation with temporal dynamics and clinical implications.Journal of thrombosis and thrombolysis · 2026Review
- Copeptin in the diagnosis and management of renal tubular disorders.Pediatric nephrology (Berlin, Germany) · 2026Review
- COPeptin Evaluation in argininevasopressin Deficiency post transsphenoidal surgery (COPED study).Pituitary · 2026Article
- Assessing the Role of Delta Copeptin in the Evaluation of SIAD and CSW.Indian journal of pediatrics · 2026Article
- Arginine Vasopressin Deficiency and Oxytocin Deficiency in the Endocrine Clinic.The Journal of clinical endocrinology and metabolism · 2026Review
- Copeptin as a dual biomarker in type 2 diabetes: association with glycemic control and diabetic kidney disease.BMC endocrine disorders · 2026Article
- Beyond Biomarkers: Blending Copeptin and Clinical Cues to Distinguish Central Diabetes Insipidus from Primary Polydipsia in Children.Biomedicines · 2025Article
- Comparative Diagnostic Performance of Copeptin After Hypertonic Saline Infusion Versus Water Deprivation Test in Pediatric Patients with Polyuria-Polydipsia Syndrome.International journal of molecular sciences · 2025Observational
- Copeptin in Acute Myocardial Infarction: Is There a Role in the Era of High-Sensitivity Troponins?Journal of cardiovascular development and disease · 2025Review
- Copeptin Hormone Concentrations in Dogs with Heart Disease and Relationship with Antidiuretic Hormone.Animals : an open access journal from MDPI · 2025Article
- Approach to the Patient With Suspected Hypotonic Polyuria.The Journal of clinical endocrinology and metabolism · 2025Article
- Arginine vasopressin and copeptin: comparative review and perspective in veterinary medicine.Frontiers in veterinary science · 2025Review
- Arginine vasopressin deficiency: diagnosis, management and the relevance of oxytocin deficiency.Nature reviews. Endocrinology · 2024Review
- Cannabinoid receptor type 1 activation causes a water diuresis by inducing an acute central diabetes insipidus in mice.American journal of physiology. Renal physiology · 2024Article
- Copeptin levels increase in response to both insulin-induced hypoglycemia and arginine but not to clonidine: data from GH-stimulation tests.Endocrine connections · 2023Article
- Cancer and the Vasopressin Gene: Radioimmunoassay Values and Commentary on Copeptin as a Plasma Marker.OncoTargets and therapy · 2023Article
- Limited Role of Endogenous Vasopressin/Copeptin in Stimulation of ACTH-Cortisol Secretion during Glucagon Stimulation Test in Humans.Biomedicines · 2022Article
- Diagnosis and Management of Central Diabetes Insipidus in Adults.The Journal of clinical endocrinology and metabolism · 2022Review
- Seasonal variation of vasopressin and its relevance for the winter peak of cardiometabolic disease: A pooled analysis of five cohorts.Journal of internal medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to correlate three commercially available copeptin assays and their diagnostic accuracy in the differential diagnosis of the polyuria-polydipsia syndrome. Analyzed data include repeated copeptin measures of 8 healthy volunteers and 40 patients with polyuria-polydipsia syndrome undergoing osmotic stimulation and of 40 patients hospitalized with pneumonia. Copeptin was measured using the automated Brahms KRYPTOR, the manual Brahms LIA and the manual Cloud Clone ELISA assay. Primary outcome was the interrater correlation coefficient (ICC) and diagnostic accuracy in the polyuria-polydipsia syndrome of the three assays. In healthy volunteers, there was a moderate correlation for the KRYPTOR and LIA (ICC 0.74; 95% CI 0.07 to 0.91), and a poor correlation for the KRYPTOR and ELISA (ICC 0.07; 95% CI - 0.06 to 0.29), as for the LIA and ELISA (ICC 0.04; 95% CI - 0.04 to 0.17). The KRYPTOR had the highest diagnostic accuracy (98% (95% CI 83 to100)), comparable to the LIA (88% (95% CI 74 to 100)), while the ELISA had a poor diagnostic accuracy (55% (95% CI 34 to 68)) in the differential diagnosis of the polyuria-polydipsia syndrome. The KRYPTOR and LIA yield comparable copeptin concentrations and high diagnostic accuracy, while the ELISA correlates poorly with the other two assays and shows a poor diagnostic accuracy for polyuria-polydipsia patients. The current copeptin cut-off is valid for the KRYPTOR and LIA assay. Our results indicate that interpretation with other assays should be performed with caution and separate validation studies are required before their use in differentiating patients with polyuria-polydipsia syndrome.Trial registration: NCT02647736 January 6, 2016/NCT01940614 September 12, 2013/NCT00973154 September 9, 2009.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.